Acute Myeloid Leukemia (AML)

People with relapsed or refractory acute myeloid leukemia (R/R) AML are asked to participate in a research study being conducted by the Albert Einstein College of Medicine.

You may be eligible to participate in this study if you:

• Are at least ≥18 years of age
• Have confirmed diagnosis of relapsed or primary refractory AML

You may not participate in this study if you:

• Have Eastern Cooperative Oncology Group (ECOG) performance status >2
• Have a history of an active or chronic autoimmune condition within the last 5 years
• Have a second primary malignancy that requires active therapy within the last 5 years
• Have a history of solid organ transplant, including corneal transplant
• Are receipt of a live-virus vaccination within 28 days of first chemotherapy dose
• Are known to be positive for HIV disease or hepatitis B or C infection
• Are pregnant or breast-feeding women

Contact Information
Joel Victor, Study Coordinator
Phone: (718) 920-6680